Inyx (IYXI) Stock Price

Inyx Price

OTC·CLOSED
0.00
​
Market closed

Revenue has compounded at 392.9% per year over the past 4 years to 49.57 M USD. Inyx's net margin stands at -62.6%, up from -97.6% several years earlier.

Inyx stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inyx business model & stock analysis

Inyx Inc, listed under the ticker IYXI with ISIN US4618681013, is a pharmaceutical company headquartered in New York City, United States. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Inyx Inc has 572 employees and completed its initial public offering on February 19, 2003. The company focuses on developing and acquiring niche pharmaceutical products and drug delivery systems for therapeutic areas such as respiratory and dermatological applications. Its operations include the development of prescription and over-the-counter pharmaceutical products, as well as specialty consulting services. Inyx Inc utilizes niche drug delivery capabilities to develop its own products, with product categories encompassing Metered Dose Inhalers (MDIs) using CFC and HFA propellants, Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays for nasal and oral use, Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions and Injectables, Solid Dose formulations, and various services including Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support, and Integrated Project Management. The company's activities are centered around creating innovative solutions in drug delivery and pharmaceutical development within specific therapeutic areas.

Frequently asked questions about Inyx

Converted at the current exchange rate, the Inyx share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Inyx.

The profit cannot currently be calculated for Inyx.

The P/E ratio cannot be calculated for Inyx at the moment.

The P/S cannot be calculated for Inyx currently.

The Eulerpool Quality Score for Inyx is 3/10.

The ISIN of Inyx is US4618681013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Inyx is 121019. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Inyx is IYXI. The ticker symbol is used to trade Inyx shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
86,652.10 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Feb 19, 2003
ISIN
US4618681013
Cusip
461868101
Market capitalization
5,311.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.24 %
Last updated Oct 19, 2026, 5:01 PM

Inyx Peer Group

Inyx Ticker

OTC · IYXI

Inyx FIGI

IYXI:US · BBG000FK0RK6IYXI:PQ · BBG000FK24M3IYXI:UV · BBG000FK2675

All fundamentals and in-depth analysis of Inyx

Our stock analysis for Inyx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inyx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.